Idera Pharma (IDRA) Reports In-Line Q2 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
Go back to Idera Pharma (IDRA) Reports In-Line Q2 Loss
August 6, 2015 7:30 AM EDT
CAMBRIDGE, Mass. and EXTON, Pa., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today reported its financial and operational results for the second quarter ended June 30, 2015.
"From a program execution perspective, we've continued to make steady progress across the board during the second quarter of 2015," stated Vincent Milano, Idera's Chief Executive Officer. "We recently announced our strategic clinical research alliance with MD Anderson, with the first planned study of this alliance... More
August 6, 2015 7:30 AM EDT
CAMBRIDGE, Mass. and EXTON, Pa., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today reported its financial and operational results for the second quarter ended June 30, 2015.
"From a program execution perspective, we've continued to make steady progress across the board during the second quarter of 2015," stated Vincent Milano, Idera's Chief Executive Officer. "We recently announced our strategic clinical research alliance with MD Anderson, with the first planned study of this alliance... More
